2023 Volume 41 Issue 1 Pages 1-9
［Objective］Recently, there are several analyses of safety in patients who received short-hydration cisplatin-based chemotherapy. But there are few same analyses in gynecologic cancer. We evaluate safety of short-hydration cisplatin-based chemotherapy in our hospital.
［Methods］Among cases of endometrial cancer in which cisplatin and doxorubicin therapy was performed between January 2017 to December 2020, we compared safety between the short-hydration regimen (SH group) and the usual regimen (non-SH group). Total volume was about 1,500 mL and total hydration time was about 4 hours in SH group. In non-SH group, volume was about 8,000 mL and time was about 20 hours.
［Results］There was no significance between the group in age, serum creatinine, creatinine clearance, regimen dose before treatment. There was no significance in rise of serum creatinine, decline of creatinine clearance, and there were no adverse events over grade 2 in renal and digestive function. 3 cases in SH group received treatment in an outpatient setting.
［Conclusions］Short-hydration cisplatin-based chemotherapy seems to be safety in gynecologic cancer, and it seems to be able to reduce the burden for patients and medical workers because of the shorten of hydration.
